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Abstract 
Background: Recombinant human bone morphogenetic protein-2 (rhBMP-2) is a powerful 
osteoinductive morphogen capable of stimulating the migration of mesenchymal stem cells (MSCs) to 
the site of implantation and inducing the proliferation and differentiation of these MSCs into 
osteoblasts. Vertebral end-plate and vertebral body resorption has been reported after interbody fusion 
with high doses of rhBMP-2. In this study, we investigated the effects of 2 rhBMP-2 doses on peri-
implant bone resorption and bone remodeling at 7 time points in an end-plate-sparing ovine interbody 
fusion model. 
Methods: Twenty-one female sheep underwent an end-plate-sparing discectomy followed by interbody 
fusion at L2-L3 and L4-L5 using a custom polyetheretherketone (PEEK) interbody fusion device. The PEEK 
interbody device was filled with 1 of 2 different doses of rhBMP-2 on an absorbable collagen sponge 
(ACS): 0.13 mg (1·) or 0.90 mg (7·). Bone remodeling and interbody fusion were assessed via high-
resolution radiography and histological analyses at 1, 2, 3, 4, 8, 12, and 20 weeks postoperatively. 
Results: Peri-implant bone resorption peaked between 3 and 8 weeks in both the 1· and the 7· rhBMP-
2/ACS-dose group. Osteoclastic activity and corresponding peri-implant bone resorption was dose-
dependent, with moderate-tomarked resorption at the 7·-dose level and less resorption at the 1·-dose 
level. Both dose (p < 0.0007) and time (p <0.0025) affected bone resorption significantly. Transient 
bone-resorption areas were fully healed by 12 weeks. Osseous bridging was seen at all but 1 spinal level 
at 12 and at 20 weeks. 
Conclusions: In the ovine end-plate-sparing interbody fusion model, rhBMP-2 dose-dependent 
osteoclastic resorption is a transient phenomenon that peaks at 4 weeks postoperatively. 
Clinical Relevance: Using the U.S. Food and Drug Administration (FDA)-approved rhBMP-2 concentration 
and matching the volume of rhBMP-2/ACS with the volume of desired bone formation within the 
interbody construct may limit the occurrence of transient bone resorption. 
 
Previous literature has demonstrated the osteoinductive capabilities of recombinant human bone 
morphogenetic protein-2 (rhBMP-2) and its ability to effect bone healing in osseous defects, long-bone 
defects, and spine fusions 1-10. Through chemotaxis, rhBMP-2 draws mesenchymal stem cells (MSCs) to 
the site of implantation while inducing the proliferation and differentiation of these MSCs into 
osteoblasts 1. The current carrier for rhBMP-2 is an absorbable collagen sponge (ACS) made of cross-
linked type-I bovine collagen11-13. 
 
In 2002, following extensive preclinical work and U.S. Food and Drug Administration (FDA)-
approved clinical studies, the combination of 1.5 mg/mL of rhBMP-2 on the ACS carrier (INFUSE Bone 
Graft;Medtronic Sofamor Danek) was approved as an autograft replacement in certain anterior lumbar 
interbody fusions. Since then, it has been used successfully to induce spine fusion.14-32 However, with 
increasing clinical use, vertebral end-plate or vertebral body resorption has been observed after 
interbody fusion with various BMP doses, surgical techniques, and interbody constructs.21,22,25,28,33,34 
This resorptive phenomenon can be difficult to visualize on radiographs but appears as decreased 
mineral density on computed tomography (CT) scans approximately 3 to 6 months after 
surgery.21,22,25,28,33,34 The resorptive zones are usually transient with progressive bone formation and 
fusion occurring overtime.21,22,25,28 A previous ovine study demonstrated that overfilling cancellous 
osseous defects with rhBMP-2/ACS and/or hyperconcentrating rhBMP-2 resulted in dose-dependent 
transient osteoclastic activity and peri-implant resorption.35 
  
The cause and histological composition of these resorption zones have not been examined in a 
clinically relevant experimental interbody fusion model. The goal of this study was to investigate the 
effects of 2 rhBMP-2 doses on periimplant bone resorption and bone remodeling at 7 time points in a 
novel end-plate-sparing ovine interbody fusion model. We hypothesize that transient osteoclastic 
resorption of peri-implant bone would occur in a dose-dependent fashion at early time points. 
Materials and Methods 
Animal Model 
The previously validated interbody fusion procedure with a retroperitoneal transpsoas approach 
in sheep was used as the experimental model.6,9,10,36 The study was approved by the Institutional Animal 
Care and Use Committee. A novel end-plate-sparing technique was utilized to mimic more current 
clinical surgical techniques with impacted interbody constructs. 
Materials and Study Design 
Twenty-one skeletally mature (2 to 3-year-old) nongravid female sheep underwent an end-
plate-sparing discectomy and interbody fusion at L2-L3 and L4-L5 using an ovine-customized 
polyetheretherketone (PEEK) interbody interbody fusion device measuring 16 ·12 · 4.5 mm with an 
internal volume of approximately 0.3 cm3. The PEEK interbody devices were filled with 1 of 2 different 
doses (1· or 7·) of rhBMP-2 on an ACS carrier (Table I). The 1·dose consisted of 0.3 mL of 0.43 mg/mL of 
rhBMP-2, for a total of 0.13 mg. This concentration was previously found to be effective for interbody 
fusion in the ovine model.6,9,10 The 7· dose consisted of 0.6 mL of 1.50 mg/mL of rhBMP-2 for a total of 
0.90 mg. Fentanyl patches were used for the management of postoperative pain. 
 
 Osteoclastic activity, bone remodeling, and the development of interbody fusion within the 
PEEK cages were studied radiographically and histologically by evaluating 3 spinal levels at 1, 2, 3, 4, 8, 
12, and 20 weeks after treatment with each of the 2 doses. At sacrifice, CT scans, high-resolution 
radiography, and histological analysis were performed. 
 
Radiographic Evaluation 
Axial CT scans with a slice thickness of 1.5 mm and sagittal and coronal reconstructions were 
performed on all 21 explanted spines (L1-L6). A highresolution radiography unit (Faxitron; Hewlett 
Packard) and film (EKTASCAN B/RA Film 4153; Kodak) were used to produce a high-resolution 
posteroanterior radiograph of the explants. Additionally, 4 sagittal slabs (6 to 7mmthick) through each 
disc space were produced and scanned using high-resolution radiography. 
Histological Studies 
Approximately 20 undecalcified histological sections were produced per level. The histological 
criterion used to assess fusion was a continuous osseous bridge from the cranial to the caudal vertebra. 
A vertebral level was considered to have solid fusion if ‡50% of the sections and corresponding 
microradiographs showed continuous osseous bridging through the thrugrowth region of the PEEK 
device, a partial fusion if <50% of the sections and corresponding microradiographs showed continuous 
osseous bridging, and no fusion if none of the sections and corresponding microradiographs showed 
continuous osseous bridging. 
Quantitative Radiography 
Faxitron high-resolution no-magnification radiographs of all 4 slabs from each of the treated 
ovine lumbar levels were scanned using a video camera (model DFC 280; Leica Microsystems). A 
millimeter scale was placed in the field, and the macroscopic magnification was kept constant during 
imaging. Image analysis software (Image-Pro Plus, version 5.1; Media Cybernetics) was used for each of 
the spatially calibrated radiographic images to measure peri-implant resorption areas. The investigators 
were blinded to the implant assignments. 
Statistical Analysis 
A regression analysis using a least squares model was performed to determine the effects of the 
dose and post-implantation time point on the quantitative radiography results for peri-implant bone 
resorption. A Student t test was used to examine differences between 2 time points. 
TABLE I Treatment Groups and Post-Implantation Time Points Evaluated 
rhBMP-2/ACS Volume* rhBMP-2 Solution 
Concentration† 
Effective rhBMP-2 
Dose/Concentration 
Postoperative Time Points 
Evaluated (wk) 
1x 1x 1 1, 2, 3, 4, 8, 12, 20 
2x 3.5x 7x 1, 2, 3, 4, 8, 12, 20 
*A volume of 0.3 mL appropriately filled the interbody construct. †The effective concentration for sheep interbody fusion has 
been reported to be 0.43 mg/mL.6,9,10 
Results 
Quantitative Radiography Showing Peri-Implant Bone Resorption Peaking Between 
3 and 8 Weeks 
Mean quantitative radiography measurements of periimplant bone resorption in the 1· and 7·-
dose groups at all time periods are shown in Figure 1. Peri-implant bone resorption peaked between 3 
and 8 weeks in both groups. Both dose (p < 0.0007) and time (p < 0.0025) affected total bone resorption 
significantly. Bone resorption was significantly greater at the 3 and 4-week time points than at the 
earliest (2-week) time point and the 2 latest (12 and 20-week) time points (a = 0.05, power =0.95). 
Radiographic and Histological Results 
At 1 Week Post-Implantation 
Radiography showed minimal-to-no remodeling of the superior or inferior cortical end plates at 
the 6 spinal levels analyzed at 1 week after treatment. Neither osteoclastic resorption nor new bone 
formation was observed within the disc spaces of any of the 6 treated levels. No osseous exostoses were 
seen. At all of the treated levels, the ACS implant was observed within the thrugrowth region of the 
PEEK interbody construct. 
At 2 Weeks Post-Implantation 
CT scans demonstrated minimal-to-no end-plate remodeling at 2 weeks post-implantation. In 
the 1·-dose group, histological images and microradiographs demonstrated intact cortical end plates 
with a very small amount of bone remodeling consisting of both osteoclastic resorption and 
intramembranous ossification (Fig. 2-A). However, in the 7·-dose group, histological analysis and 
microradiography showed resorption of the cortical end plates that ranged from a subtle rarified 
appearance (Fig. 2-B) to focal resorption of the cortical end plates. Histological analysis showed 
osteoclastic resorption extending into osseous trabeculae of the vertebral bodies at all 3 spinal levels in 
the 7·-dose group and at 1 level in the 1·-dose group. Evidence of osteoid (pink) and intramembranous 
ossification on mineralized de novo osseous spicules (green) was observed within the PEEK interbody 
construct at a 1·-dose spinal level (Fig. 2-C), and focal osteoclastic resorption of the cortical end plates 
was observed adjacent to the PEEK interbody construct at another 1·-dose spinal level (Fig. 2-D). The 
ACS implant was observed within the PEEK interbody construct at all levels treated 2 weeks before 
analysis (Figs. 2-A and 2-B). 
At 3 Weeks Post-Implantation 
Radiographically, all levels treated with the 7· dose demonstrated moderate-to-marked peri-
implant resorption. One of the 3 levels treated with the 1· dose demonstrated minimal-to-moderate 
resorption on radiography. On histological analysis, all of the 7·-dose spinal levels and 1 of the 3 levels 
treated with the 1· dose showed a rarified appearance of the cortical end plates that correlated with 
increased focal osteoclastic resorption of the cortical osseous end plates extending well into osseous 
trabeculae of the adjacent vertebral bodies (Figs. 3-A, 3-B, and 3-C). Some unmineralized osteoid formed 
via intramembranous ossification was observed at the periphery of the resorption zones (Fig. 3-D). 
Loose granulation tissues were found within the PEEK implant and within peri-implant resorption zones. 
The other 2 levels treated with the 1· dose showed less bone resorption (Figs. 4-A and 4-B). The ACS 
implant was observed within the PEEK interbody construct at all treated levels. 
 
Fig. 1 Mean quantitative radiography measurements of peri-implant resorption areas at all time periods following 
application of 1· and 7· doses of rhBMP-2. 
Peri-implant bone resorption peaked between 3 and 8 weeks in both dosing groups. 
 Fig. 2 Figs. 2-A and 2-B Stained undecalcified sections from spinal levels 2 weeks after treatment with a 1· dose 
(Fig. 2-A) or 7· dose (Fig. 2-B) of rhBMP-2. Both histological images demonstrate substantial preservation of the 
cortical end plates. No remodeling of the superior or inferior cortical end plates was observed adjacent to the PEEK 
interbody construct in the 1·-dose group at 2 weeks, but subtle remodeling changes were observed in the 7·-dose 
group (arrow). The ACS implant is seen within the thrugrowth region of the PEEK interbody constructs. Fig. 2-C 
Evidence of osteoid (pink) and intramembranous ossification on mineralized de novo osseous spicules (green) were 
observed within the PEEK interbody construct in a 1·-dose spinal level at the 2-week time point (trichrome stain, 
original magnification = 200·). Fig. 2-D Focal osteoclastic resorption of the cortical end plates was observed 
adjacent to the PEEK interbody construct at a 1·-dose spinal level at the 2-week time point (trichrome stain, 
original magnification = 200·). 
At 4 Weeks Post-Implantation 
All 7·-dose spinal levels demonstrated moderate-to-marked peri-implant bone resorption on radiographs, 
with histological analysis showing substantial end-plate changes and bone resorption extending well into osseous 
trabeculae of the adjacent vertebral bodies. Histological analysis showed the greatest amount of bone resorption 
at 4 weeks post-implantation (Fig. 5-A). Unmineralized osteoid formed via intramembranous ossification was 
frequently observed at the periphery and within the resorption zones. Early stages of de novo bone formation 
resulting in early histologically evident fusion were found at 1 of the 3 levels in the 7·-dose group (Fig. 5-B). One of 
the 3 levels in the 1·-dose group demonstrated moderate resorption radiographically and histologically, whereas 
the other 2 levels in the 1·-dose group showed less peri-implant resorption (Fig. 5-C). Granulation tissues were 
found within the PEEK implant and within peri-implant resorption zones. In 4 of the 6 treated levels, the ACS 
implant was observed within the PEEK interbody construct. 
At 8 Weeks Post-Implantation 
At 8 weeks, CTscans showed minimal end-plate changes at the 1·-dose spinal levels and 
moderate-to-marked end-plate and vertebral body resorption at 1 level that had received the 7· dose. 
This was confirmed by histological analysis as osseous resorption with osteoclasts present on the 
surfaces of osteopenic trabeculae. Histological analysis of the 7·-dose spinal levels showed substantial 
end-plate changes and boneremodeling areas. Although end-plate changes and bone resorption 
extended well into osseous trabeculae of the vertebral bodies, osseous healing with hypodense 
mineralized trabeculae could be observed within these resorption zones and in the thrugrowth region of 
the disc space on the microradiograph (Fig. 6-A). Numerous foci of intramembranous ossification are 
seen on the surfaces of the developing osseous fusion mass within the thrugrowth region of the PEEK 
device at a 7·-dose level (Fig. 6-B). At higher magnification, hypertrophied osteoblasts in 
intramembranous ossification on osseous trabeculae of the developing fusion mass were observed 
within the PEEK interbody fusion device (Fig. 6-C). All 3 of the 7·-dose levels showed evidence of 
exostoses, which in some cases bridged the disc spaces. Intramembranous and endochondral 
ossification within the thrugrowth region of the PEEK interbody fusion device was a routine histological 
finding in both treatment groups. Osteoclastic activity on rarified trabeculae was observed in bone of 
the adjacent vertebral body, some distance away from the PEEK implant, and within the thrugrowth 
region of the PEEK device (Fig. 6-D). ACS was not observed at any treated levels at 8 weeks on 
histological analysis. An incidental histological finding was intracellular PEEK particulate debris and an 
attendant focal mild chronic inflammatory host response consisting primarily of macrophages with some 
foreign-body giant cells at a majority of the treated levels (Fig. 6-E). One unusual histological finding was 
a fluid-filled lined cyst adjacent to the PEEK device in the 1·-dose group (Fig. 6-F). 
 
Fig. 3 Figs. 3-A and 3-B Stained undecalcified sections from spinal levels 3 weeks after treatment with a 7· dose of 
rhBMP-2. Fig. 3-C Histological analysis showed substantial end-plate changes as well as osteoclastic resorption 
extending well into osseous trabeculae of the superior and/or inferior vertebral bodies at all 3 spinal levels in the 
7·-dose group at 3 weeks (trichrome stain, original magnification = 200·). Fig. 3-D Some unmineralized osteoid 
formed via intramembranous ossification was observed at the periphery of the resorption zones (trichrome stain, 
original magnification = 313·). 
  
Fig. 4 Stained undecalcified sections from spinal levels 3 week after treatment with a 1· dose of rhBMP-2. One of 
the 3 levels treated with the 1· dose demonstrated moderate resorption of the end plates on histological analysis 
(Fig. 4-A), whereas the other 2 levels treated with the 1· dose showed less bone resorption (Fig. 4-B) and 
substantial preservation of the cortical end plates. 
 
Fig. 5 Figs. 5-A and 5-B Stained undecalcified section (Fig. 5-A) from, and microradiograph (Fig. 5-B) of, spinal levels 
4 weeks after treatment with a 7· dose of rhBMP-2. Histological analysis showed substantial end-plate changes as 
well as bone resorption extending well into osseous trabeculae of the superior and/or inferior vertebral bodies at 
all 3 levels in the 7·-dose group at 4 weeks. Unmineralized osteoid formed via intramembranous ossification can be 
observed at the periphery of the resorption zones. The microradiograph shows hypodense osteopenic de novo 
bone in previous resorption zones and in the thrugrowth region of the disc space, indicative of the early stages of 
histologically evident fusion at 4 weeks. Fig. 5-C A stained undecalcified section from a spinal level 4 weeks after 
treatment with the 1· dose, showing less bone resorption and substantial preservation of the cortical end plates. 
At 12 Weeks Post-Implantation 
At 12 weeks, CT scans showed limited evidence of end-plate remodeling and demonstrated 
bone formation through the thrugrowth region of the PEEK interbody devices. Except for 1 of the 1·-
dose spinal levels, all treated levels demonstrated complete bridging bone on CT. The CT findings 
correlated well with the findings of the histological analysis, which showed 1 fusion, 1 partial fusion, and 
1 non-fusion at the 1·-dose levels and 2 fusions and 1 partial fusion at the 7·-dose levels. In both groups, 
the bone was isodense with respect to native trabeculae on microradiography (Fig. 7). With the 
exception of some pitting of the end plates at 1 of the 1·-dose levels, end-plate changes were not 
observed. Microradiography showed that previous bone-remodeling areas that had extended well into 
the vertebral bodies were now fully healed, with isodense-to-slightly hypodense trabeculae. Bridging 
and non-bridging exostoses were a frequent finding in both groups. All 6 treated levels had intracellular 
PEEK particulate debris and an attendant focal mild chronic inflammatory host response consisting 
primarily of macrophages with some foreign-body giant cells. One unusual histological finding was a 
small subclinical infection with numerous segmented neutrophils limited to tissue adjacent to the PEEK 
implant at the 1·-dose spinal level at which histological analysis showed non-fusion. 
At 20 Weeks Post-Implantation 
At 20 weeks, all treated levels showed osseous fusion across the disc space on CTscans. Except 
for 1 of the 1·-dose levels, all treated levels had either a partial or complete fusion seen on histological 
analysis. One level in the 7·-dose group demonstrated solid fusion outside the PEEK device and fusion 
progression within the device. In both treatment groups, the incorporated bone of the fusion mass was 
isodense with respect to native trabeculae onmicroradiography (Fig. 8). PEEK particulate debris was not 
observed. 
 
Fig. 6 Fig. 6-A Microradiograph of a spinal level 8 weeks after treatment with a 1· dose of rhBMP-2, showing end-
plate changes and bone resorption extending well into osseous trabeculae of the superior and inferior vertebral 
bodies. Osseous healing with hypodensemineralized trabeculae can be observed within these resorption zones and 
in the thrugrowth region of the disc space. Fig. 6-B Numerous foci of intramembranous ossification (arrows) are 
seen on the surfaces of the developing osseous fusion mass within the thrugrowth region of the PEEK device in this 
7·-dose spinal level at 8 weeks (hematoxylin and eosin, original magnification = 79·). Fig. 6-C Higher-magnification 
micrograph of the boxed region in Fig. 6-B, showing hypertrophied osteoblasts in intramembranous ossification on 
osseous trabeculae of the developing fusion mass within the PEEK interbody fusion device (hematoxylin and eosin, 
original magnification= 200·). Fig. 6-DOsteoclastic resorption of bonewas still observed8weeks post-implantation in 
a 7·-dose spinal level at8weeks (hematoxylin and eosin, original magnification = 200·). Fig. 6-E An incidental finding 
of the 8-week histological analysis was intracellular PEEK particulate debris (birefringentmaterial) and an attendant 
focalmild chronic inflammatory host response (hematoxylin and eosin, partially polarized light, 
originalmagnification = 200·). Fig. 6-F One unusual histological finding in the 1·-dose group was a fluid-filled lined 
cyst (arrow) adjacent to the PEEK device. 
 
Fig. 7 Fig. 7-A Stained undecalcified section from a spinal level showing solid fusion 12 weeks after treatment with 
a 7· dose of rhBMP-2. Fig. 7-B Microradiograph of a spinal level 12 weeks after treatment with a 7· dose 
demonstrates bridging bone from the cranial to caudal vertebral bodies that is isodense with respect to the native 
trabeculae. Previous bone-remodeling areas (arrows) that had extended well into the vertebral bodies are now 
fully healed with isodense-to-slightly hypodense osteopenic trabeculae. Note the difference in trabecular thickness 
between these areas (arrows) and native trabeculae of the vertebral bodies. 
 
Fig. 8 Microradiograph of a spinal level showing histological evidence of solid fusion with dense mineralized 
trabeculae in the thrugrowth region of the disc space 20 weeks after treatment with a 7· dose of rhBMP-2. 
Discussion 
In this end-plate-sparing sheep model, osteoclastic activity and corresponding peri-implant bone 
resorption was dosedependent, with the 7·-dose spinal levels demonstrating moderate-to-marked 
resorption and the 1·-dose levels demonstrated minimal-to-no resorption. By 20 weeks, transient bone-
resorption effects were not observed and bridging bone was seen regardless of the rhBMP-2 dose. The 
time to healing was not altered by increasing the dose. Findings similar to those in the current study 
were previously reported by Toth et al.35, whose chronologic study demonstrated bone resorption with 
subsequent osseous healing in association with application of rhBMP-2 in a corticocancellous sheep 
distal femoral model. With immediate access to cancellous bone in that distal femoral model, a 7· dose 
of rhBMP-2 caused increased osteoclastic activity and peri-implant bone resorptionwith marked 
resorption by 1 week35. Inall of their treatment groups, the osteoclastic response was transient with no 
osteoclastic activity and substantial new bone formation by 4 weeks35. Immediate cancellous access 
caused osteoclastic resorption to peak at 1week in that study, whereas the delayed cancellous access 
associated with the cortical end-plate-sparing model in our study resulted in osteoclastic resorption 
peaking at 3 to 4 weeks. 
 As can happen in any animal model, inter-animal variability with respect to bone remodeling 
was observed in the current study. Transient bone-resorption areas varied in both size and location, 
with the greatest variability in size occurring in the 7·-dose group. The location of the transient bone-
resorption areas varied from cranial to caudal in relation to the thrugrowth region of the PEEK implant 
and was also seen posterior to the implant, particularly at the 3-week time point in the 7·-dose group. 
While settling of the PEEK interbody fusion device into the cortical end plate was observed in both 
groups, dose-dependent subsidence was not observed. A lateral 2-screw and single-rod construct was 
used to provide some postoperative stability and may have limited the potential for substantial 
subsidence to occur. 
 
The literature suggests that BMPs can affect osteoclastic activity, with a stimulatory effect on 
the formation of osteoclasts or their bone resorptive capacity, or both.37-44 
 
Although a number of FDA-approved clinical investigations have been conducted with rhBMP-
2/ACS,15-22,24 to our knowledge transient bone resorption has been reported in only 1. Burkus and 
colleagues21,22 reported that 14 (18%) of 79 patients developed remodeling zones between 3 and 12 
months after treatment with 8.4 to 12 mg of rhBMP-2/ACS combined with 2 threaded allograft dowels. 
By 24 months, all remodeling zones had resolved and a 99% fusion rate had been achieved. 
 
Other clinical studies have demonstrated transient bone resorption following implantation of 
rhBMP-2/ACS. Meisel and colleagues28 reported bone resorption following posterior lumbar interbody 
fusion with application of 12 mg of rhBMP-2/ACS within PEEK interbody spacers. At 3 months  
postoperatively, 17 patients were noted to have reduced mineral density on CTscans. However, these 
resorption zones were transient, resolving by 6 months. Pradhan et al.34 reported resorption of the graft 
and end plates following the use of rhBMP-2/ACS with ring allografts. Finally, Hansen and Sasso25 
reported on a single patient who had a transient resorptive response following the use of rhBMP-2/ACS 
in anterior lumbar interbody fusion with an allograft ring. 
 
One limitation of the current study is the fact that the variables of increasing rhBMP-2/ACS fill of 
the interbody fusion device and hyperconcentration of the rhBMP-2 were not examined individually as 
potential drivers of heightened osteoclastic resorption. However, it is important to recall that the 1· and 
7· doses that we selected had been examined previously in an ovine corticocancellous distal femoral 
model35. As discussed above, these doses demonstrated the largest difference in transient osteoclastic 
activity and peri-implant bone resorption. The 7· dose represents a worst-case scenario in which the 
user underdilutes the rhBMP-2 to increase the solution concentration while overfilling the thrugrowth 
region of the interbody fusion device. While this is unlikely to occur in clinical practice, it is possible and 
was therefore included as a worst-case dosing scenario. Importantly, in the previous ovine distal femoral 
corticocancellous model35, overfilling with (2·) and hyperconcentration of (3.5·) the rhBMP-2 were 
examined as standalone variables and both resulted in heightened osteoclastic activity and peri-implant 
bone resorption compared with what was seen in the 1· group. As 1· and 7· doses performed similarly 
regardless of whether the distal femoral or cortical end-plate-sparing interbody fusionmodel was used, 
it can be assumed that both bone-forming environments are susceptible to rhBMP-2 dose-dependent 
transient osteoclastic activity and peri-implant bone resorption. 
 
In conclusion, osteoclastic activity and corresponding peri-implant bone resorption were rhBMP-
2-dose-dependent in an end-plate-sparing ovine interbody fusion model in which a custom-designed 
PEEK interbody construct had been implanted via a transpsoas retroperitoneal approach; 7·-dose levels 
resulted in moderate-to-marked resorption while 1·-dose levels resulted in minimal-to-no resorption. By 
20 weeks, transient bone-resorption effects were not observed and bridging bone was seen by the 
blinded assessors regardless of the dose. Increasing the dose had no effect on the time to healing. Using 
the FDA-approved rhBMP-2 concentration and matching the volume of rhBMP-2/ACS with the volume 
of the desired bone formation may limit the occurrence of transient bone resorption. 
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